PICO Portalanswers from OpenAlex
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
PaperCitations, authors & open-access status
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma is a paper indexed in PICO Portal from OpenAlex.
How many citations does Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma have?
PICO Portalcitation count
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma has 5,921 citations in the OpenAlex counts PICO Portal stores.
When was Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma published?
PICO Portalyear
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma has 2015 year in the PICO Portal index.
What is the open-access status of Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma?
PICO Portaloa status
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma has bronze oa status in the PICO Portal index.
What is the DOI of Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma?
PICO Portaldoi
The DOI for Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma is on the source record.
What is the PMID of Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma?
PICO Portalpmid
The PMID for Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma is on the source record.
What is the OpenAlex record for Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma?
PICO Portalopenalex
The OpenAlex for Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma is on the source record.